Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus

Author(s): Sarmad Said, German T. Hernandez.

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry

Volume 11 , Issue 3 , 2013

Become EABM
Become Reviewer

Abstract:

The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.

Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 11
ISSUE: 3
Year: 2013
Page: [203 - 206]
Pages: 4
DOI: 10.2174/187152571103140120103032
Price: $58

Article Metrics

PDF: 31